Changes to the Code
H.R. 1768 · Lower Costs for Everyday Americans Act · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
In committee · step 2 of 5
2 U.S.C. § 901a Enforcement of budget goal
2 changes the bill asks for here, 1 carried out
- Not carried out:
in subparagraph (D), by striking
such that,
and all that follows and insertingsuch that the payment reduction shall be 2.0 percent.
; and“such that,” isn't in § 901a(6)(D) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“such that,” not found in /us/usc/t2/s901a/6/D - Carried out:
by adding at the end the following:
(F) On the date on which the President submits the budget under section 1105 of title 31, United States Code, for fiscal year 2033, the President shall order a sequestration of payments for the Medicare programs specified in section 256(d), effective upon issuance, such that, …
The section already has a provision under this letter or number, so it would have two.
This bill puts a provision under a letter or number this section already uses, so the section would have two. The law has probably changed since the bill was written.
§ 901a(6)–(8)
Start of § 901a to (6)(F) unchanged ·
(i) with respect to the first 5 months in which such order is effective for such fiscal year, the payment reduction shall be 2.0 percent; and
(ii) with respect to the last 7 months in which such order is effective for such fiscal year, the payment reduction shall be 0 percent.
(F) [inserted: On the date on which the President submits the budget under section 1105 of title 31, United States Code, for fiscal year 2033, the President shall order a sequestration of payments for the Medicare programs specified in section 256(d), effective upon issuance, such that, notwithstanding the 2 percent limit specified in subparagraph (A) for such payments—]
(i) [inserted: with respect to the first 2 months in which such order is effective for such fiscal year, the payment reduction shall be 2.0 percent; and]
(ii) [inserted: with respect to the last 10 months in which such order is effective for such fiscal year, the payment reduction shall be 0 percent.]
(7) Adjustment for Medicare If the percentage reduction for the Medicare programs would exceed 2 percent for a fiscal year in the absence of paragraph (6), OMB shall increase the reduction for all other discretionary appropriations and direct spending under paragraph (4) by a uniform percentage to a level sufficient to achieve the reduction required by paragraph (4) in the non-defense function.
(8) Implementation of reductions Any reductions imposed under this section shall be implemented in accordance with section 906(k) of this title.
Rest of § 901a unchanged ·
5 U.S.C. § 5314 Positions at level III
1 change the bill asks for here, 1 carried out
- Carried out:
in section 5314, by adding at the end the following:
Under Secretary of Commerce for Communications and Information.; and
§ 5314(111)
Start of § 5314 unchanged ·
Director of the Office of Financial Research.
Director of the National Reconnaissance Office.
Special Counsel of the Office of Special Counsel.
[inserted: Under Secretary of Commerce for Communications and Information.]
6 U.S.C. § 575 Regional emergency communications coordination
1 change the bill asks for here, 1 carried out
- Carried out:
Section 1805(d)(2) of the Homeland Security Act of 2002 (6 U.S.C. 575(d)(2)) is amended by striking
Assistant Secretary for Communications and Information of the Department of Commerce
and insertingUnder Secretary of Commerce for Communications and Information
.
§ 575(d)Duties(1)–(4)
Start of § 575 to (d) unchanged ·
(1) assessing the survivability, sustainability, and interoperability of local emergency communications systems to meet the goals of the National Emergency Communications Plan;
(2) reporting annually to the relevant Regional Administrator, the Assistant Director for Emergency Communications, the Chairman of the Federal Communications Commission, and the [struck: Assistant][inserted: Under] Secretary [inserted: of Commerce ]for Communications and Information [struck: of the Department of Commerce ]on the status of its region in building robust and sustainable interoperable voice and data emergency communications networks and, not later than 60 days after the completion of the initial National Emergency Communications Plan under section 572 of this title, on the progress of the region in meeting the goals of such plan;
(3) ensuring a process for the coordination of effective multijurisdictional, multi-agency emergency communications networks for use during natural disasters, acts of terrorism, and other man-made disasters through the expanded use of emergency management and public safety communications mutual aid agreements; and
(4) coordinating the establishment of Federal, State, local, and tribal support services and networks designed to address the immediate and critical human needs in responding to natural disasters, acts of terrorism, and other man-made disasters.
7 U.S.C. § 950bb–6 Federal broadband program coordination
2 changes the bill asks for here, 1 carried out
- Not carried out:
in subsection (d)(1), in the heading, by striking
Assistant secretary
and insertingUnder secretary
; and“Assistant secretary” isn't in § 950bb–6(d)(1) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“Assistant secretary” not found in /us/usc/t7/s950bb–6/d/1 - Carried out:
by striking
Assistant Secretary
each place the term appears and insertingUnder Secretary
.
§ 950bb–6(a)–(c)
§ 950bb–6. Federal broadband program coordination
(a) Consultation between USDA and NTIA The Secretary shall consult with the [struck: Assistant][inserted: Under] Secretary to assist in the verification of eligibility of the broadband loan and grant programs of the Department of Agriculture. In providing assistance under the preceding sentence, the [struck: Assistant][inserted: Under] Secretary shall make available the broadband assessment and mapping capabilities of the National Telecommunications and Information Administration.
(b) Consultation between USDA and FCC
(1) By USDA The Secretary shall consult with the Commission before providing broadband assistance for a project to serve an area with respect to which another entity is receiving Connect America Fund or Mobility Fund support under the Federal universal service support mechanisms established under section 254 of title 47.
(2) By FCC The Commission shall consult with the Secretary before offering or providing Connect America Fund or Mobility Fund support under the Federal universal service support mechanisms established under section 254 of title 47 to serve an area with respect to which another entity has received broadband assistance under a loan or grant program of the Department of Agriculture.
(c) Report to Congress Not later than 1 year after December 20, 2018, the Secretary, the Commission, and the [struck: Assistant][inserted: Under] Secretary shall submit to the Committee on Agriculture and the Committee on Energy and Commerce of the House of Representatives and the Committee on Agriculture, Nutrition, and Forestry and the Committee on Commerce, Science, and Transportation of the Senate a report on how best to coordinate federally supported broadband programs and activities in order to achieve the following objectives:
(1) Promote high-quality broadband service that meets the long-term needs of rural residents and businesses, by evaluating the broadband service needs in rural areas for each decade through 2050.
(2) Support the long-term viability, sustainability, and utility of federally supported rural broadband infrastructure, by analyzing the technical capabilities of the technologies currently available and reasonably expected to be available by 2035 to meet the broadband service needs of rural residents identified under paragraph (1), including by analyzing the following:
§ 950bb–6(d)Definitions(1)–(3)
(c)(2)(A)–(3)(D) unchanged ·
(d) Definitions In this section:
(1) Assistant Secretary The term “[struck: Assistant][inserted: Under] Secretary” means the [struck: Assistant][inserted: Under] Secretary of Commerce for Communications and Information.
(2) Commission The term “Commission” means the Federal Communications Commission.
(3) Rural area The term “rural area” has the meaning given the term in section 950bb(b)(3) of this title.
15 U.S.C. § 9801 Defined term
3 changes the bill asks for here, 2 carried out
- Carried out:
by redesignating paragraphs (1) and (2) as subparagraphs (A) and (B), respectively, and adjusting the margins accordingly; and
- Not carried out:
by striking In this title, the term COVID–19 public health emergency— and inserting the following:In this title: (1) COVID–19 public health emergency.— The term
COVID–19 public health emergency
—; andWe couldn't carry out this instruction.
Technical detail
the provision inserted says more than the words struck - Carried out:
by adding at the end the following:
(2) Music tourism.— The term “music tourism” means— (A) the act of traveling to a State or locality to visit historic or modern day music-related attractions, including museums, studios, venues of all sizes, and other sites related to music; or (B) the act of traveling to a …
§ 9801(A)–(2)
§ 9801. Defined term
In this title:1
[struck: (1)] [inserted: (A)] COVID–19 public health emergency The term “COVID–19 public health emergency”—
(A) means the public health emergency first declared on January 31, 2020, by the Secretary of Health and Human Services under section 247d of title 42 with respect to COVID–19; and
(B) includes any renewal of such declaration pursuant to such section 247d of title 42.
[struck: (2)] [inserted: (B)] Music tourism The term “music tourism” means—
(A) the act of traveling to a State or locality to visit historic or modern day music-related attractions, including museums, studios, venues of all sizes, and other sites related to music; or
(B) the act of traveling to a State or locality to attend a music festival, a concert, or other live musical performance or music-related special event.
(2) [inserted: Music tourism.—] [inserted: The term “music tourism” means—]
(A) [inserted: the act of traveling to a State or locality to visit historic or modern day music-related attractions, including museums, studios, venues of all sizes, and other sites related to music; or]
(B) [inserted: the act of traveling to a State or locality to attend a music festival, a concert, or other live musical performance or music-related special event.]
15 U.S.C. § 9803 Responsibilities of the Assistant Secretary of Commerce for Travel and Tourism
5 changes the bill asks for here, 2 carried out
- Not carried out:
in paragraph (2), by striking
; and
and inserting a semicolon;
“; and” isn't in § 9803(b)(2) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“; and” not found in /us/usc/t15/s9803/b/2 - Not carried out:
in paragraph (3), by striking the period at the end and inserting
; and
; andThe bill strikes “.” at the end of § 9803(b)(3), but the text there doesn't end with it. The law may have changed since the bill was drafted.
Technical detail
“.” is not at the end of /us/usc/t15/s9803/b/3 - Not carried out:
by adding at the end the following:
(4) identify locations and events in the United States that are important to music tourism and facilitate and promote domestic travel and tourism to those locations and events..
The law already reads this way: § 9803(b)(4) is already as the bill would have it.
Technical detail
already there: /us/usc/t15/s9803/b/4 reads as the bill would have it - Carried out:
Section 605 of the Visit America Act (15 U.S.C. 9803) is amended by striking subsection (d) and inserting the following:
(d) Facilitation of international business and leisure travel.— The Assistant Secretary, in coordination with relevant Federal agencies, shall strive to increase and facilitate international business and leisure travel to the United States and ensure competitiveness by— (1) …
- Carried out:
Section 605(f) of the Visit America Act (15 U.S.C. 9803(f)) is amended by adding at the end the following:
(4) Report on goals relating to domestic and international travel.— Not later than 1 year after the date of enactment of the American Music Tourism Act, and every 2 years thereafter, the Assistant Secretary shall submit to the Subcommittee on Tourism, Trade, and Export Promotion …
The section already has a provision under this letter or number, so it would have two.
This bill puts a provision under a letter or number this section already uses, so the section would have two. The law has probably changed since the bill was written.
1 of the 5 changes this bill asks for here is already in the law as it stands, and was not made a second time. The bill, or another making the same changes, has probably become law since.
§ 9803(c)–(d)
Start of § 9803 to (c)(2) unchanged ·
(3) provide recommendations for policy enhancements and efficiencies; and
(4) provide policy recommendations regarding the gig economy as it relates to travel and tourism.
(d) Facilitation of international business and leisure travel[inserted: .—] The Assistant Secretary, in coordination with relevant Federal agencies, shall strive to increase and facilitate international business and leisure travel to the United States and ensure competitiveness by—
(1) facilitating large meetings, incentives, conferences, and exhibitions in the United States;
§ 9803(f)Reporting requirements(3)–(4)
(d)(2)–(f)(3) unchanged ·
(B) shall include questions in the Survey of International Air Travelers regarding wait-times, visits to public lands, and State data, to the extent applicable.
(4) Report on goals relating to domestic and international travel Not later than 1 year after October 9, 2026, and every 2 years thereafter, the Assistant Secretary shall submit to the Committee on Commerce, Science, and Transportation of the Senate and the Committee on Energy and Commerce of the House of Representatives a report of activities, findings, achievements, and vulnerabilities relating to the goals described in subsections (a) through (d).
(4) [inserted: Report on goals relating to domestic and international travel.—] [inserted: Not later than 1 year after the date of enactment of the American Music Tourism Act, and every 2 years thereafter, the Assistant Secretary shall submit to the Subcommittee on Tourism, Trade, and Export Promotion of the Committee on Commerce, Science, and Transportation of the Senate and the Subcommittee on Innovation, Data, and Commerce of the Committee on Energy and Commerce of the House of Representatives a report of activities, findings, achievements, and vulnerabilities relating to the goals described in subsections (a) through (d).]
17 U.S.C. § 1201 Circumvention of copyright protection systems
1 change the bill asks for here, 1 carried out
- Carried out:
Section 1201(a)(1)(C) of title 17, United States Code, is amended by striking
Assistant Secretary for Communications and Information of the Department of Commerce
and insertingUnder Secretary of Commerce for Communications and Information
.
§ 1201(a)(1)(B)–(C)
Start of § 1201 to (a)(1)(A) unchanged ·
(B) The prohibition contained in subparagraph (A) shall not apply to persons who are users of a copyrighted work which is in a particular class of works, if such persons are, or are likely to be in the succeeding 3-year period, adversely affected by virtue of such prohibition in their ability to make noninfringing uses of that particular class of works under this title, as determined under subparagraph (C).
(C) During the 2-year period described in subparagraph (A), and during each succeeding 3-year period, the Librarian of Congress, upon the recommendation of the Register of Copyrights, who shall consult with the [struck: Assistant][inserted: Under] Secretary [inserted: of Commerce ]for Communications and Information [struck: of the Department of Commerce ]and report and comment on his or her views in making such recommendation, shall make the determination in a rulemaking proceeding for purposes of subparagraph (B) of whether persons who are users of a copyrighted work are, or are likely to be in the succeeding 3-year period, adversely affected by the prohibition under subparagraph (A) in their ability to make noninfringing uses under this title of a particular class of copyrighted works. In conducting such rulemaking, the Librarian shall examine—
(i) the availability for use of copyrighted works;
(ii) the availability for use of works for nonprofit archival, preservation, and educational purposes;
Rest of § 1201 unchanged ·
21 U.S.C. § 355 New drugs
1 change the bill asks for here, 1 carried out
- Carried out:
Section 505(j)(3) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(3)) is amended by adding at the end the following:
(H) (i) Upon request (in controlled correspondence or an analogous process) by a person that has submitted or intends to submit an abbreviated application under this subsection for a drug that is required by regulation to contain one or more of the same inactive ingredients in …
The section already has a provision under this letter or number, so it would have two.
This bill puts a provision under a letter or number this section already uses, so the section would have two. The law has probably changed since the bill was written.
§ 355(j)Abbreviated new drug applications(3)–(4)
Start of § 355 to (j)(3)(H)(iii)(II) unchanged ·
(iv) If the Secretary makes a written determination described in clause (iii)(II), the Secretary shall provide notice and a copy of the written determination to the person making the request under clause (i).
(v) The disclosures authorized under clauses (i) and (ii) are disclosures authorized by law, including for purposes of section 1905 of title 18. This subparagraph shall not otherwise be construed to authorize the disclosure of nonpublic qualitative or quantitative information about the ingredients in a listed drug, or to affect the status, if any, of such information as trade secret or confidential commercial information for purposes of section 331(j) of this title, section 552 of title 5, or section 1905 of title 18.
(H)
(i) [inserted: Upon request (in controlled correspondence or an analogous process) by a person that has submitted or intends to submit an abbreviated application under this subsection for a drug that is required by regulation to contain one or more of the same inactive ingredients in the same concentrations as the listed drug referred to, or for which the Secretary determines there is a scientific justification for an approach that is in vitro, in whole or in part, to be used to demonstrate bioequivalence for a drug if such a drug contains one or more of the same inactive ingredients in the same concentrations as the listed drug referred to, the Secretary shall inform the person whether such drug is qualitatively and quantitatively the same as the listed drug. The Secretary may also provide such information to such a person on the Secretary’s own initiative during the review of an abbreviated application under this subsection for such drug.]
(ii) [inserted: Notwithstanding section 301(j), if the Secretary determines that such drug is not qualitatively or quantitatively the same as the listed drug, the Secretary shall identify and disclose to the person—]
(I) [inserted: the ingredient or ingredients that cause such drug not to be qualitatively or quantitatively the same as the listed drug; and]
(II) [inserted: for any ingredient for which there is an identified quantitative deviation, the amount of such deviation.]
(iii) [inserted: If the Secretary determines that such drug is qualitatively and quantitatively the same as the listed drug, the Secretary shall not change or rescind such determination after the submission of an abbreviated application for such drug under this subsection unless—]
(I) [inserted: the formulation of the listed drug has been changed and the Secretary has determined that the prior listed drug formulation was withdrawn for reasons of safety or effectiveness; or]
(II) [inserted: the Secretary makes a written determination that the prior determination must be changed because an error has been identified.]
(iv) [inserted: If the Secretary makes a written determination described in clause (iii)(II), the Secretary shall provide notice and a copy of the written determination to the person making the request under clause (i).]
(v) [inserted: The disclosures authorized under clauses (i) and (ii) are disclosures authorized by law, including for purposes of section 1905 of title 18, United States Code. This subparagraph shall not otherwise be construed to authorize the disclosure of nonpublic qualitative or quantitative information about the ingredients in a listed drug, or to affect the status, if any, of such information as trade secret or confidential commercial information for purposes of section 301(j) of this Act, section 552 of title 5, United States Code, or section 1905 of title 18, United States Code.]
(4) Subject to paragraph (5), the Secretary shall approve an application for a drug unless the Secretary finds—
(A) the methods used in, or the facilities and controls used for, the manufacture, processing, and packing of the drug are inadequate to assure and preserve its identity, strength, quality, and purity;
Rest of § 355 unchanged ·
21 U.S.C. § 355c Research into pediatric uses for drugs and biological products
11 changes the bill asks for here, 6 carried out
- Carried out:
by redesignating subparagraphs (B) and (C) as subparagraphs (C) and (D), respectively; and
The section already has a provision under this letter or number, so it would have two.
- Carried out:
by striking subparagraph (A) and inserting the following:
(A) In general.— For purposes of paragraph (1)(B), the investigation described in this paragraph is a molecularly targeted pediatric cancer investigation of— (i) the drug or biological product for which the application referred to in such paragraph is submitted; or (ii) such …
- Carried out:
Section 505B(e)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355c(e)(1)) is amended by adding at the end the following:
The Secretary shall determine whether subparagraph (A) or (B) of subsection (a)(1) applies with respect to an application before the date on which the applicant is required to submit the initial pediatric study plan under paragraph (2)(A).
. - Not carried out:
Section 505B(a)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355c(a)(1)) is amended by adding at the end the following:
(C) Rule of construction.— No application that is subject to the requirements of subparagraph (B) shall be subject to the requirements of subparagraph (A), and no application (or supplement to an application) that is subject to the requirements of subparagraph (A) shall be …
The law already reads this way: § 355c(a)(1)(C) is already as the bill would have it.
Technical detail
already there: /us/usc/t21/s355c/a/1/C reads as the bill would have it - Not carried out:
in paragraph (3)(C), as redesignated by paragraph (1)(A) of this subsection, by striking
investigations described in this paragraph
and insertinginvestigations referred to in subparagraph (A)
; and“investigations described in this paragraph” isn't in § 355c(a)(3)(C) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“investigations described in this paragraph” not found in /us/usc/t21/s355c/a/3/C - Not carried out:
in paragraph (3)(D), as redesignated by paragraph (1)(A) of this subsection, by striking
the assessments under paragraph (2)(B)
and insertingthe assessments required under paragraph (1)(A)
.“the assessments under paragraph (2)(B)” isn't in § 355c(a)(3)(D) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“the assessments under paragraph (2)(B)” not found in /us/usc/t21/s355c/a/3/D~2 - Carried out:
in paragraph (1), by striking
Beginning 270
and insertingNoncompliance letter.—Beginning 270
; - Carried out:
by striking
The drug or
and insertingEffect of noncompliance.—The drug or
; and - Not carried out:
by striking
(except that the drug or biological product shall not be subject to action under section 303)
and inserting(except that the drug or biological product shall be subject to action under section 303 only if such person demonstrated a lack of due diligence in satisfying the applicable requirement)
; and“(except that the drug or biological product shall not be subject to action under section 303)” isn't in § 355c(d)(2) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“(except that the drug or biological product shall not be subject to action under section 303)” not found in /us/usc/t21/s355c/d/2 - Carried out:
by adding at the end the following:
(3) Limitation.— The Secretary shall not issue enforcement actions under section 303 for failures under this subsection in the case of a drug or biological product that is no longer marketed..
The section already has a provision under this letter or number, so it would have two.
- Not carried out:
Section 505B(d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355c(d)), as amended by subsection (a), is further amended by adding at the end the following:
(4) Due diligence.— Before the Secretary may conclude that a person failed to submit or otherwise meet a requirement as described in the matter preceding paragraph (1), the Secretary shall— (A) issue a noncompliance letter pursuant to paragraph (1); (B) provide such person with …
The law already reads this way: § 355c(d)(4) is already as the bill would have it.
Technical detail
already there: /us/usc/t21/s355c/d/4 reads as the bill would have it
This bill puts a provision under a letter or number this section already uses, so the section would have two. The law has probably changed since the bill was written.
2 of the 11 changes this bill asks for here are already in the law as it stands, and were not made a second time. The bill, or another making the same changes, has probably become law since.
§ 355c(a)New drugs and biological products(2)–(4)
Start of § 355c to (a)(2)(B)(ii) unchanged ·
(iii) Information on extrapolation A brief documentation of the scientific data supporting the conclusion under clauses (i) and (ii) shall be included in any pertinent reviews for the application under section 355 of this title or section 262 of title 42.
(3) 1 Molecularly targeted pediatric cancer investigation
(A) In general[inserted: .—] For purposes of paragraph (1)(B), the investigation described in this paragraph is a molecularly targeted pediatric cancer investigation of—
(i) the drug or biological product for which the application referred to in such paragraph is submitted; or
(ii) such drug or biological product used in combination with—
(I) an active ingredient of a drug or biological product—
(aa) for which an approved application under section [struck: 355][inserted: 505](j) under this [struck: title][inserted: Act] or under section [struck: 262][inserted: 351](k) of [struck: title][inserted: the] [struck: 42][inserted: Public] [inserted: Health Service Act ]is in effect; and
(bb) that is determined by the Secretary, after consultation with the applicant, to be part of the standard of care for treating a pediatric cancer; or
(II) an active ingredient of a drug or biological product—
(aa) for which an approved application under section [struck: 355][inserted: 505](b) of this [struck: title][inserted: Act] or section [struck: 262][inserted: 351](a) of [struck: title][inserted: the] [struck: 42][inserted: Public] [inserted: Health Service Act ]to treat an adult cancer is in effect and is held by the same person submitting the application under paragraph (1)(B); and
(bb) that is directed at a molecular target that the Secretary determines to be substantially relevant to the growth or progression of a pediatric cancer.
(B) [inserted: Additional requirements.—]
(i) [inserted: Design of investigation.—] [inserted: A molecularly targeted pediatric cancer investigation referred to in subparagraph (A) shall be designed to yield clinically meaningful pediatric study data that is gathered using appropriate formulations for each age group for which the study is required, regarding dosing, safety, and preliminary efficacy to inform potential pediatric labeling.]
(ii) [inserted: Limitation.—] [inserted: An investigation described in subparagraph (A)(ii) may be required only if the drug or biological product for which the application referred to in paragraph (1)(B) contains either—]
(I) [inserted: a single new active ingredient; or]
(II) [inserted: more than one active ingredient, if an application for the combination of active ingredients has not previously been approved but each active ingredient is in a drug product that has been previously approved to treat an adult cancer.]
(iii) [inserted: Results of already-completed preclinical studies of application drug.—] [inserted: With respect to an investigation required pursuant to paragraph (1)(B), the Secretary may require the results of any completed preclinical studies relevant to the initial pediatric study plan be submitted to the Secretary at the same time that the initial pediatric study plan required under subsection (e)(1) is submitted.]
(iv) [inserted: Rule of construction regarding inactive ingredients.—] [inserted: With respect to a combination of active ingredients referred to in subparagraph (A)(ii), such subparagraph shall not be construed as addressing the use of inactive ingredients with such combination.]
[struck: (B)] [inserted: (C)] Additional requirements
(i) Design of investigation A molecularly targeted pediatric cancer investigation referred to in subparagraph (A) shall be designed to yield clinically meaningful pediatric study data that is gathered using appropriate formulations for each age group for which the study is required, regarding dosing, safety, and preliminary efficacy to inform potential pediatric labeling.
(ii) Limitation An investigation described in subparagraph (A)(ii) may be required only if the drug or biological product for which the application referred to in paragraph (1)(B) contains either—
(I) a single new active ingredient; or
(II) more than one active ingredient, if an application for the combination of active ingredients has not previously been approved but each active ingredient is in a drug product that has been previously approved to treat an adult cancer.
(iii) Results of already-completed preclinical studies of application drug With respect to an investigation required pursuant to paragraph (1)(B), the Secretary may require the results of any completed preclinical studies relevant to the initial pediatric study plan be submitted to the Secretary at the same time that the initial pediatric study plan required under subsection (e)(1) is submitted.
(iv) Rule of construction regarding inactive ingredients With respect to a combination of active ingredients referred to in subparagraph (A)(ii), such subparagraph shall not be construed as addressing the use of inactive ingredients with such combination.
[struck: (C)] [inserted: (D)] Extrapolation of data Paragraph (2)(B) shall apply to investigations referred to in subparagraph (A) to the same extent and in the same manner as paragraph (2)(B) applies with respect to the assessments required under paragraph (1)(A).
(D) Deferrals and waivers Deferrals and waivers under paragraphs (4) and (5) shall apply to investigations described in this paragraph to the same extent and in the same manner as such deferrals and waivers apply with respect to the assessments required under paragraph (1)(A).
(4) Deferral
§ 355c(d)Submission of assessments and reports on the investigation(1)–(2)
(a)(4)(A)–(c)(2) unchanged ·
(d) Submission of assessments and reports on the investigation If a person fails to submit a required assessment described in subsection (a)(2) or the investigation described in subsection (a)(3), fails to meet the applicable requirements in subsection (a)(4), or fails to submit a request for approval of a pediatric formulation described in subsection (a) or (b), in accordance with applicable provisions of subsections (a) and (b), the following shall apply:
(1) Noncompliance letter [inserted: Noncompliance letter.—]Beginning 270 days after July 9, 2012, the Secretary shall issue a non-compliance letter to such person informing them of such failure to submit or meet the requirements of the applicable subsection. Such letter shall require the person to respond in writing within 45 calendar days of issuance of such letter. Such response may include the person’s request for a deferral extension if applicable. Such letter and the person’s written response to such letter shall be made publicly available on the Internet Web site of the Food and Drug Administration 60 calendar days after issuance, with redactions for any trade secrets and confidential commercial information. If the Secretary determines that the letter was issued in error, the requirements of this paragraph shall not apply. The Secretary shall inform the Pediatric Advisory Committee of letters issued under this paragraph and responses to such letters.
(2) Effect of noncompliance [inserted: Effect of noncompliance.—]The drug or biological product that is the subject of an assessment described in subsection (a)(2) or the investigation described in subsection (a)(3), applicable requirements in subsection (a)(4), or request for approval of a pediatric formulation, may be considered misbranded solely because of that failure and subject to relevant enforcement action (except that the drug or biological product shall be subject to action under section 333 of this title only if such person demonstrated a lack of due diligence in satisfying the applicable requirement), but such failure shall not be the basis for a proceeding—
(A) to withdraw approval for a drug under section 355(e) of this title; or
(B) to revoke the license for a biological product under section 262 of title 42.
§ 355c(d)–(e)
(d)(3)–(4) unchanged ·
(B) provide such person with a 45-day period beginning on the date of receipt of such noncompliance letter to respond in writing as set forth in such paragraph; and
(C) after reviewing such written response, determine whether the person demonstrated a lack of due diligence in satisfying such requirement.
(3) [inserted: Limitation.—] [inserted: The Secretary shall not issue enforcement actions under section 303 for failures under this subsection in the case of a drug or biological product that is no longer marketed.]
(e) Pediatric study plans
(1) In general An applicant subject to subsection (a) shall submit to the Secretary an initial pediatric study plan prior to the submission of the assessments described under subsection (a)(2) or the investigation described in subsection (a)(3). The Secretary shall determine whether subparagraph (A) or (B) of subsection (a)(1) applies with respect to an application before the date on which the applicant is required to submit the initial pediatric study plan under paragraph (2)(A).1[inserted: The Secretary shall determine whether subparagraph (A) or (B) of subsection (a)(1) applies with respect to an application before the date on which the applicant is required to submit the initial pediatric study plan under paragraph (2)(A).]
(2) Timing; content; meetings
(A) Timing An applicant shall submit the initial pediatric study plan under paragraph (1)—
Rest of § 355c unchanged ·
21 U.S.C. § 355c–1 Report
4 changes the bill asks for here, 2 carried out
- Carried out:
in paragraph (11), by striking the semicolon at the end and inserting , including an evaluation of compliance with deadlines provided for in deferrals and deferral extensions
;
; - Not carried out:
in paragraph (15), by striking
and
at the end;The bill strikes “and” at the end of § 355c–1(b)(15), but the text there doesn't end with it. The law may have changed since the bill was drafted.
Technical detail
“and” is not at the end of /us/usc/t21/s355c–1/b/15 - Not carried out:
in paragraph (16), by striking the period at the end and inserting
; and
; andThe bill strikes “.” at the end of § 355c–1(b)(16), but the text there doesn't end with it. The law may have changed since the bill was drafted.
Technical detail
“.” is not at the end of /us/usc/t21/s355c–1/b/16 - Carried out:
by adding at the end the following:
(17) a listing of penalties, settlements, or payments under section 303 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353) for failure to comply with requirements under such section 505B, including, for each penalty, settlement, or payment, the name of the drug, the …
The section already has a provision under this letter or number, so it would have two.
This bill puts a provision under a letter or number this section already uses, so the section would have two. The law has probably changed since the bill was written.
§ 355c–1(b)Contents(10)–(12)
Start of § 355c–1 to (b)(9) unchanged ·
(10) an assessment of the successes of and limitations to studying drugs for rare diseases under such sections 355a and 355c of this title;
(11) an assessment of the impact of the amendments to such section 355c of this title made by the FDA Reauthorization Act of 2017 on pediatric research and labeling of drugs and biological products and pediatric labeling of molecularly targeted drugs and biological products for the treatment of cancer, including an evaluation of compliance with deadlines provided for in deferrals and deferral extensions[inserted: , including an evaluation of compliance with deadlines provided for in deferrals and deferral extensions];
(12) an assessment of the efforts of the Secretary to implement the plan developed under section 505C–1 of the Federal Food, Drug, and Cosmetic Act,1 regarding earlier submission of pediatric studies under sections 355a and 355c of this title and section 262(m) of title 42, including—
(A) the average length of time after the approval of an application under section 355(b)(1) of this title or section 262(a) of title 42 before studies conducted pursuant to such section 355a of this title, 355c of this title, or section 262(m) of title 42 are completed, submitted, and incorporated into labeling;
§ 355c–1(b)–(c)
(b)(12)(B)–(15) unchanged ·
(16) the Secretary’s assessment of the overall impact of the amendments made by section 504 of the FDA Reauthorization Act of 2017 on the conduct and effectiveness of pediatric cancer research and the orphan drug program, as well any subsequent recommendations; and
(17) a listing of penalties, settlements, or payments under section 333 of this title for failure to comply with requirements under such section 355c of this title, including, for each penalty, settlement, or payment, the name of the drug, the sponsor thereof, and the amount of the penalty, settlement, or payment imposed.
(17) [inserted: a listing of penalties, settlements, or payments under section 303 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353) for failure to comply with requirements under such section 505B, including, for each penalty, settlement, or payment, the name of the drug, the sponsor thereof, and the amount of the penalty, settlement, or payment imposed; and]
(c) Stakeholder comment At least 180 days prior to the submission of each report under subsection (a), the Secretary shall consult with representatives of patient groups (including pediatric patient groups), consumer groups, regulated industry, academia, and other interested parties to obtain any recommendations or information relevant to the report including suggestions for modifications that would improve pediatric drug research and pediatric labeling of drugs and biological products.